To access this material please log in or register

Register Authorize

Effect of ubidecarenone on content of some markers for inflammation and remodeling in patients with chronic heart failure

Kukharchik G. A., Sichinava L. B., Gaykovaya L. B., Konstantinova I. V., Burbello A. T.
«North-Western State Medical University named after I. I Mechnikov» MPH RF, Kirochnaya 41, Saint-Petersburg, 191015

Keywords: inflammation, myocardial infarction, treatment, myocardial remodeling, CHF

DOI: 10.18087/rhfj.2014.5.1947

Background. Chronic HF remains one of essential causes for disability and mortality. New therapies for HF are continually being searched for. A promising approach is the use of co-enzyme Q10 drugs. Effects of these drugs in HF are still understudied. Aim. To evaluate effects of ubidecarenone (Kudevit®) on myocardial inflammation and LV remodeling in patients with CHF after MI. Materials and methods. The study included 108 patients with FC II–III CHF. The patients were randomized to two groups: Group 1, patients receiving a standard, optimum adjusted therapy plus ubidecarenone for 3 months; Group 2, patients receiving the optimum adjusted, standard therapy alone. A 6‑min walk test and evaluation of the clinical condition using the CCS scale were performed for all patients at baseline and at 3 months. In addition to the general clinical examination, the following laboratory markers were measured at baseline and at 3 months: N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), galectin-3, and gene 2 expressed enhancing growth factor (ST2). For evaluation of postinfarction LV remodeling, time-dependent EchoCG changes were studied. Results. After 3 months of therapy, the clinical course of CHF improved in both groups. In Group 1 patients receiving ubidecarenone, as distinct from Group 2, LV end-diastolic and end-systolic volumes were decreased and EF was increased. After 3 months of therapy, levels of NT-proBNP and hsCRP were reduced in both groups but levels of galectin-3 and ST2 were reduced only in Group 2 patients. Conclusion. Supplementation of the base therapy with ubidecarenone restricted progression of postinfarction remodeling in patients with FC II–III CHF after MI. The ubidecarenone treatment alleviated the fibrosing process in myocardium.
  1. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная недостаточность. 2013;14 (7):379–472.
  2. Фомин И. В. Артериальная гипертония в Российской Федерации – последние десять лет. Что дальше? Сердце. 2007;6 (3):120–122.
  3. Go AS, Mozaffarian D, Roger VL et al. Executive summary: heart disease and stroke statistics-–2013 update: a report from the American Heart Association. Circulation. 2013 Jan 1;127 (1):143–52.
  4. Бадин Ю. В., Фомин И. В. Выживаемость больных ХСН в когортной выборке Нижегородской области (данные 1998–2002 годов.). Всероссийская конференция ОССН: «Сердечная недостаточность, 2005 год» – М., 2005. – с. 31–32.
  5. Медведев О. С., Каленикова Е. И., Городецкая Е. А., Шашурин Д. А. Коэнзим Q10 в кардиологической практике – теоретические основы и результаты клинических исследований. Российский Медицинский Журнал. Доступно на: http://www.rmj.ru / articles_6724.htm
  6. Pepe S, Marasco SF, Haas SJ et al. Coenzyme Q10 in cardiovascular disease. Mitochondrion. 2007 Jun;7 (Suppl): S154–67.
  7. Mortensen SA, Kumar A, Dolliner P et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. Доступно на: http://spo.escardio.org / SessionDetails.aspx?eevtid=61&fp=440#.Uu8vKvl_vhQ
  8. Iqbal N, Wentworth B, Choudhary R et al. Cardiac biomarkers: new tools for heart failure management. Cardiovasc Diagn Ther. 2012 Jun;2 (2):147–64.
  9. Panagopoulou V, Deftereos S, Kossyvakis C et al. NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem. 2013;13 (2):82–94.
  10. Lok DJ, Klip IT, Lok SI et al. Incremental prognostic power of no­vel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol. 2013 Sep 15;112 (6):831–7.
  11. Лакомкин С. В., Скворцов А. А., Горюнова Т. В. и др. Галектин-3 – новый маркер диагностики и прогноза хронической сердечной недостаточности. Кардиология. 2012;3:45–52.
  12. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12 (4):200–10.
Kukharchik G. A., Sichinava L. B., Gaykovaya L. B. et al. Effect of ubidecarenone on content of some markers for inflammation and remodeling in patients with chronic heart failure. Russian Heart Failure Journal. 2014;15 (5): 288–293

To access this material please log in or register

Register Authorize
Ru En